Tech Company Financing Transactions
Cartesian Therapeutics Funding Round
Cartesian Therapeutics closed a $150 million financing round on 5/26/2026. Investors included K2 HealthVentures.
Transaction Overview
Company Name
Announced On
5/26/2026
Transaction Type
Debt
Amount
$150,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds from the initial tranche under the credit facility are expected to allow the Company to accelerate the ongoing investment in the commercial launch preparation activities for Descartes-08 in myasthenia gravis (MG) and myositis and to extend cash runway into 2028.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7495 New Horizon Way
Frederick, MD 21703
USA
Frederick, MD 21703
USA
Phone
Undisclosed
Email Address
Overview
Our mission to expand the reach of cell therapy to patients with autoimmune diseases is deeply rooted in our core values, which drive our dedication to excellence and inspire every aspect of our work.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carsten Brunn
Chief Financial Officer
Blaine Davis
Chief Operating Officer
Emily English
VP - General Counsel
Matthew Bartholomae
VP - R & D
Peter Traber
Browse more venture capital transactions:
Prev: 5/26/2026: Phytolon venture capital transaction
Next: 5/26/2026: Avrea venture capital transaction
Share this article
About Our VC Transactions Data
We report on all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs